AU2014291149B2 - Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor - Google Patents

Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor Download PDF

Info

Publication number
AU2014291149B2
AU2014291149B2 AU2014291149A AU2014291149A AU2014291149B2 AU 2014291149 B2 AU2014291149 B2 AU 2014291149B2 AU 2014291149 A AU2014291149 A AU 2014291149A AU 2014291149 A AU2014291149 A AU 2014291149A AU 2014291149 B2 AU2014291149 B2 AU 2014291149B2
Authority
AU
Australia
Prior art keywords
benzopyran
amino
optionally substituted
oxo
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014291149A
Other languages
English (en)
Other versions
AU2014291149A1 (en
Inventor
Kimiko Morimoto
Keiichi Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of AU2014291149A1 publication Critical patent/AU2014291149A1/en
Application granted granted Critical
Publication of AU2014291149B2 publication Critical patent/AU2014291149B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
AU2014291149A 2013-07-18 2014-07-17 Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor Ceased AU2014291149B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-149690 2013-07-18
JP2013149690 2013-07-18
PCT/JP2014/069026 WO2015008827A1 (ja) 2013-07-18 2014-07-17 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤

Publications (2)

Publication Number Publication Date
AU2014291149A1 AU2014291149A1 (en) 2016-02-11
AU2014291149B2 true AU2014291149B2 (en) 2017-05-04

Family

ID=52346269

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014291149A Ceased AU2014291149B2 (en) 2013-07-18 2014-07-17 Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor

Country Status (22)

Country Link
US (3) US20150353519A1 (enExample)
EP (2) EP3078372B1 (enExample)
JP (2) JP5802868B2 (enExample)
CN (1) CN105407887B (enExample)
AU (1) AU2014291149B2 (enExample)
CA (1) CA2918325C (enExample)
CY (2) CY1118140T1 (enExample)
DK (2) DK3078372T3 (enExample)
ES (2) ES2642440T3 (enExample)
HR (2) HRP20161317T1 (enExample)
HU (2) HUE034661T2 (enExample)
IL (1) IL243550B (enExample)
LT (2) LT2929880T (enExample)
NO (1) NO3078372T3 (enExample)
PL (2) PL2929880T3 (enExample)
PT (2) PT2929880T (enExample)
RS (2) RS55394B1 (enExample)
RU (2) RU2750540C2 (enExample)
SI (2) SI2929880T1 (enExample)
SM (3) SMT201700080T1 (enExample)
TW (1) TWI603965B (enExample)
WO (1) WO2015008827A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137708A1 (zh) * 2017-01-26 2018-08-02 重庆莱美药业股份有限公司 一种纳米炭-铁复合体系及其组合物、制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023714A1 (de) * 1995-12-21 1997-07-03 Siemens Aktiengesellschaft Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5922755A (en) * 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
BR112014002407A2 (pt) 2011-08-30 2017-02-21 Toyama Chemical Co Ltd método para melhorar a terapia contra doenças autoimunes tais como artrite reumatóide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023714A1 (de) * 1995-12-21 1997-07-03 Siemens Aktiengesellschaft Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TANAKA ET AL, J Pharmacobio Dyn, Vol.15, No.11, 1992, Page.641-647 *
YOO LIM KAM ET AL: "Synthesis and bradykinin inhibitory activity of novel non-peptide compounds, and evaluation of in Vivo analgesic activity", Bioorganic & medicinal chemistry, Vol. 18, No. 6, 2010, pp.2327-36 *

Also Published As

Publication number Publication date
CA2918325C (en) 2018-06-26
RS55394B1 (sr) 2017-04-28
SMT201700080B (it) 2017-03-08
WO2015008827A1 (ja) 2015-01-22
SMT201700080T1 (it) 2017-03-08
EP3078372B1 (en) 2017-09-13
PL3078372T3 (pl) 2018-02-28
LT2929880T (lt) 2016-11-25
SI2929880T1 (sl) 2016-12-30
US9918963B2 (en) 2018-03-20
CY1118140T1 (el) 2017-06-28
AU2014291149A1 (en) 2016-02-11
EP2929880A1 (en) 2015-10-14
RU2750540C2 (ru) 2021-06-29
EP2929880A4 (en) 2015-10-14
US20160228404A1 (en) 2016-08-11
ES2642440T3 (es) 2017-11-16
DK3078372T3 (en) 2017-10-16
DK2929880T3 (da) 2017-01-02
HRP20161317T1 (hr) 2016-12-16
HUE029800T2 (en) 2017-04-28
TW201536764A (zh) 2015-10-01
JP5802868B2 (ja) 2015-11-04
PT2929880T (pt) 2016-11-08
HUE034661T2 (en) 2018-02-28
EP2929880B1 (en) 2016-09-14
US20150353519A1 (en) 2015-12-10
EP3078372A1 (en) 2016-10-12
PT3078372T (pt) 2017-10-18
IL243550B (en) 2019-06-30
CN105407887A (zh) 2016-03-16
CA2918325A1 (en) 2015-01-22
HK1222556A1 (zh) 2017-07-07
JP6060231B2 (ja) 2017-01-11
CN105407887B (zh) 2018-09-04
SI3078372T1 (en) 2018-01-31
US20160228406A1 (en) 2016-08-11
ES2593527T3 (es) 2016-12-09
RU2641301C2 (ru) 2018-01-17
SMT201700606T1 (it) 2018-01-11
NO3078372T3 (enExample) 2018-02-10
RU2017131951A (ru) 2019-02-06
TWI603965B (zh) 2017-11-01
HRP20171497T1 (hr) 2017-11-17
IL243550A0 (en) 2016-02-29
LT3078372T (lt) 2017-11-27
RU2017131951A3 (enExample) 2020-12-18
RU2016105141A (ru) 2017-08-23
CY1119496T1 (el) 2018-03-07
JP2016034953A (ja) 2016-03-17
PL2929880T3 (pl) 2017-03-31
RS56489B1 (sr) 2018-01-31
JPWO2015008827A1 (ja) 2017-03-02

Similar Documents

Publication Publication Date Title
CN101820848B (zh) 抑制n-酰基乙醇胺水解性酸酰胺酶的组合物和方法
JP6411680B1 (ja) Ｌｓｄ１阻害剤を用いて多発性硬化症を処置する方法
JP2021505565A (ja) 補体活性のモジュレータ
CN1198747A (zh) 作为金属蛋白酶和tnf释放抑制剂的硫取代的肽
TW202106290A (zh) 用於調節補體活性之組成物及方法
WO2024056028A1 (en) Analgesic polypeptide
US20060111436A1 (en) Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US9918963B2 (en) Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor
TW201625264A (zh) 水晶體硬化抑制劑
EP2338908A1 (fr) Peptides comportant des modifications de type post-translationnel et leur utilisation dans le cadre du traitement de pathologies auto-immunes
HK1222556B (en) Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor
US7183375B2 (en) Inhibitors for continuous activation for calcineurin
TW201929850A (zh) 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired